These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 32734482)

  • 1. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis.
    Favalli EG
    Rheumatol Ther; 2020 Sep; 7(3):473-516. PubMed ID: 32734482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periodontal Disease as a Risk Factor for Rheumatoid Arthritis: A Systematic Review.
    Kaur S; White S; Bartold M
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-12. PubMed ID: 27820156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis.
    Maioli G; Caporali R; Favalli EG
    Expert Opin Drug Discov; 2022 Aug; 17(8):799-813. PubMed ID: 35757853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
    Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical features of rheumatoid arthritis.
    Grassi W; De Angelis R; Lamanna G; Cervini C
    Eur J Radiol; 1998 May; 27 Suppl 1():S18-24. PubMed ID: 9652497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis.
    Yip RML; Yim CW
    J Clin Rheumatol; 2021 Dec; 27(8):e516-e524. PubMed ID: 31876844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.
    Lazzerini PE; Capecchi PL; Guidelli GM; Selvi E; Acampa M; Laghi-Pasini F
    Drug Des Devel Ther; 2016; 10():3083-3098. PubMed ID: 27713619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints.
    Jarlborg M; Gabay C
    Cytokine; 2022 Jan; 149():155742. PubMed ID: 34688020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Strand V; Boklage SH; Kimura T; Joly F; Boyapati A; Msihid J
    Arthritis Res Ther; 2020 Oct; 22(1):250. PubMed ID: 33081825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in the treatment of rheumatoid arthritis and beyond.
    Shetty A; Hanson R; Korsten P; Shawagfeh M; Arami S; Volkov S; Vila O; Swedler W; Shunaigat AN; Smadi S; Sawaqed R; Perkins D; Shahrara S; Sweiss NJ
    Drug Des Devel Ther; 2014; 8():349-64. PubMed ID: 24729685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Nutritional Interventions on Key Cytokine Pathways in Rheumatoid Arthritis and Its Implications for Comorbid Depression: Is a More Comprehensive Approach Required?
    Lanspa M; Kothe B; Pereira MR; Kesselman MM; Petrosky SN
    Cureus; 2022 Aug; 14(8):e28031. PubMed ID: 35990558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
    Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms.
    Moreland LW; Curtis JR
    Semin Arthritis Rheum; 2009 Oct; 39(2):132-43. PubMed ID: 19022481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extra-articular Manifestations and Comorbidity in Rheumatoid Arthritis: Potential Impact of Pre-Rheumatoid Arthritis Prevention.
    Giles JT
    Clin Ther; 2019 Jul; 41(7):1246-1255. PubMed ID: 31196641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarilumab: patient-reported outcomes in rheumatoid arthritis.
    Crotti C; Biggioggero M; Becciolini A; Favalli EG
    Patient Relat Outcome Meas; 2018; 9():275-284. PubMed ID: 30154675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis.
    Li X; Yuan FL; Lu WG; Zhao YQ; Li CW; Li JP; Xu RS
    Biochem Biophys Res Commun; 2010 Jun; 397(2):131-5. PubMed ID: 20513356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.
    Choy EHS; Calabrese LH
    Rheumatology (Oxford); 2018 Nov; 57(11):1885-1895. PubMed ID: 29186541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extra-articular manifestations and complications of rheumatoid arthritis.
    Young A; Koduri G
    Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):907-27. PubMed ID: 17870035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.